Media stories about Moleculin Biotech (NASDAQ:MBRX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Moleculin Biotech earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.8194029450588 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Moleculin Biotech (NASDAQ: MBRX) to Begin Preparing Clinical Testing Sites for Leukemia Treatment (missionir.com)
- Cubs pitcher Jon Lester hits first career home run Tuesday night (wisdomsave.com)
- Recent FDA Decisions and Clinical Trial Developments Influencing Current Biotech Run (prnewswire.co.uk)
- Moleculin Biotech, Inc. (MBRX) closed at $2.71 in the last trading session (newstrendstoday.com)
- Moleculin Begins Clinical Testing Site Development Efforts in Poland; Selects Bioscience SA as Polish CRO (finance.yahoo.com)
Separately, ValuEngine cut shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 6th.
Moleculin Biotech (NASDAQ:MBRX) traded down 4.51% during midday trading on Tuesday, reaching $2.54. 439,061 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $1.89 and a 200 day moving average price of $1.33. Moleculin Biotech has a 12-month low of $0.71 and a 12-month high of $6.85. The company’s market cap is $45.10 million.
Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Monday, May 15th. The company reported ($0.02) EPS for the quarter. On average, analysts expect that Moleculin Biotech will post ($0.34) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was published by BBNS and is owned by of BBNS. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/markets/moleculin-biotech-nasdaqmbrx-receives-daily-news-impact-rating-of-0-15/1410514.html.
About Moleculin Biotech
Moleculin Biotech, Inc is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).
Receive News & Ratings for Moleculin Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc. and related companies with our FREE daily email newsletter.